4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

키워드

참고문헌 (70)

1. Vinay, D. S, "Immunotherapy of cancer by 4-1BB", Mol. Cancer Ther, 11, pp.1062~1070 (2012)
2. Kwon, B. S., "cDNA sequences of two inducible T-cell genes", Proc. Nat. Acad. Sci. U.S.A, 86, pp.1963~1967 (1989)
3. Schwarz, H., "A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor", tumor-necrosis-factor receptor family, 1983, pp.134, 295~298
4. Vinay, D. S., "TNF superfamily: costimulation and clinical applications", Cell Biol. Int, 33, pp.453~465 (2009)
5. Vinay, D. S, "Genes, transcripts and proteins of CD137 receptor and ligand. In: CD137 pathway: immunology and diseases (Ed Chen L)", pp.1~14 (2006), Springer
6. Pollok, K. E., "Inducible T cell antigen 4-1BB. Analysis of expression and function", J. Immunol, 150, pp.771~781 (1993)
7. Garni-Wagner, B. A., "4-1BB is expressed on CD45RAhiROhi transitional T cell in humans", Cell Immunol, 169, pp.91~98 (1996)
8. Watts, T. H., "TNF", TNFR family members in costimulation of T cell responses, 2005, pp.23, 23~68
9. Croft, M., "Co-stimulatory members of TNFR family: keys to effective T-cell immunity", Nature Rev. Immunol, 3, pp.609~620 (2003)
10. Shuford, W. W., "4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification of in vivo cytotoxic T cell response", J. Exp. Med, 186, pp.47~55 (1997)
11. Seo, S. K., "4-1BB-mediated immunotherapy of rheumatoid arthritis", Nature Med, 10, pp.1088~1094 (2004)
12. Takahashi, C., "4-1BB is a bona-fide CD8 T cell survival signal", J. Immunol, 162, pp.5037~5040 (1999)
13. DeBenedette, M. A., "Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus", J. Immunol, 163, pp.4833~4841 (1999)
14. Kwon, B. S., "Immune responses in 4-1BB (CD137)-deficient mice", J. Immunol, 168, pp.5483~5490 (2002)
15. Sun, Y., "Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis", J. Immunol, 168, pp.1457~1465 (2002)
16. Foell, J., "CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZWF1 mice", J. Clin. Invest, 111, pp.1505~1518 (2003)
17. Sun, Y., "Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease", Nature Med, 8, pp.1405~1413 (2003)
18. Agarwal, A., "The role of positive costimulatory molecules in transplantation and tolerance", Curr. Opin. Organ. Transplant, 13, pp.366~372 (2008)
19. Zhang, G. B., "Characterization and application of three novel monoclonal antibodies against human 4-1BB: distinct epitopes of human 4-1BB on lung tumor cells and immune cells", Tissue Antigens, 70, pp.470~479 (2007)
20. Broll, K., "CD137 expression in tumor vessel walls. High correlation with malignant tumors", Am. J. Clin. Pathol, 115, pp.543~549 (2001)
21. Wan, Y. L., "Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity", World J. Gasteroenterol, 10, pp.195~199 (2004)
22. Palma, C., "CD137 and CD137 ligand constitutively expressed on human T and B leukemia cells signal proliferation and survival", Int. J. Cancer, 108, pp.390~398 (2004)
23. Ho, W. T., "Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression", Cancer Res, 73, pp.652~661 (2013)
24. Anderson, M. W., "CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications", Am. J. Pathol, 181, pp.795~803 (2012)
25. Shao, Z., "CD137 ligand, a member of the tumor necrosis factor family, regulated immune responses via reverse signal transduction", J. Leukobiol, 89, pp.21~29 (2010)
26. Melero, I., "Monoclonal antibodies against the 4-1BB T-cell activating molecule eradicate established tumors", Nature Med, 3, pp.682~685 (1997)
27. Tirapu, I., "Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti- CD137 monoclonal antibodies and alloantigens", Int. J. Cancer, 110, pp.51~60 (2004)
28. Xu, D., "NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation", Int. J. Cancer, 109, pp.499~506 (2004)
29. Sabel, M. S., "Monoclonal antibodies directed against the T cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenograft in severe combined immunodeficient mice", J. Immunother, 23, pp.362~369 (2000)
30. Kim, J. A., "Divergent effects of 4-1BB antibodies on anti-tumor immunity and on tumor- reactive T-cell generation", Cancer Res, 61, pp.2031~2037 (2001)
31. Wilcox, R. A., "Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors", J. Clin. Invest, 109, pp.651~659 (2002)
32. May, K. F., "Anti-4-1BB monoclonal antibody enhances rejection of large burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells", Cancer Res, 62, pp.3459~3465 (2002)
33. Miller, R. E., "4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner", J. Immunol, 169, pp.1792~1800 (2002)
34. Murillo, O., "In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb", Eur. J. Immunol, 39, pp.2424~2436 (2009)
35. Ju, S. A., "Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice", Int. J. Cancer, 122, pp.2784~2790 (2008)
36. Palazón, A., "Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes", Cancer Res, 71, pp.801~811 (2011)
37. June, C. H., "Adoptive T cell therapy for cancer in clinic", J. Clin. Invest, 117, pp.1466~1476 (2007)
38. Hernandez-Chacon, J. A., "Costimulation through the CD137", 4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function, 2011, pp.34, 236~250
39. Zhu, B. Q., "CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4 (+) Th1 responses", Biomed. Pharmacother, 63, pp.509~516 (2009)
40. Lu, P. H., "A novel population of expanded human CD3+CD56+ cell derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency", J. Immunol, 153, pp.1687~1696 (1994)
41. Verneris, M. R., "Low levels of Her2", neu expressed by Ewing’s family tumor cell lines can redirect cytokine-induced killer cells, 2005, pp.11, 4561~4570
42. Hassan, R., "Mesothelin targeted cancer immunotherapy", Eur. J. Cancer, 44, pp.46~53 (2008)
43. Carpenito, C., "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains", Proc. Natl. Acad. Sci. U. S. A, 106, pp.3360~3365 (2009)
44. Tammana, S., "4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies", Human Gene Ther, 21, pp.75~86 (2010)
45. Degang, S., "Improved survival provided by CD137 costimulatory signaling to folate receptor-redirected T cells results in tumor localization and eradication", Cancer Res, 171, pp.4617~4627 (2011)
46. Ye, Z., "Gene therapy of cancer using single-chain Fv fragments specific for 4-1BB", Nature Med, 8, pp.343~348 (2002)
47. Xu, D., "NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation", Int. J. Cancer, 109, pp.499~506 (2004)
48. Tirapu, I., "Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti- CD137 monoclonal antibodies and alloantigens", Int. J. Cancer, 110, pp.51~60 (2004)
49. Ito, F., "Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines", Cancer Res, 64, pp.8411~8419 (2004)
50. Kocak, E., "Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity", Cancer Res, 66, pp.7276~7284 (2006)
51. Sin, J. I., "Combined stimulation of TLR9 and 4-1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites", Cancer Lett, 3330, pp.190~199 (2013)
52. Chen, S. H., "Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation", Mol. Ther, 2, pp.39~46 (2000)
53. Shi, W., "Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment", Anticancer Res, 26, pp.3445~3453 (2006)
54. Carmeliet, P., "Angiogenesis in cancer and other diseases", Nature, 407, pp.249~257 (2000)
55. Wu, H. C, "Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy", J. Cancer Mol, 4, pp.17~22 (2008)
56. Ko, E., "Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad anti angiogenic immunity", Cancer Res, 67, pp.7875~7884 (2007)
57. Li, B., "Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb", Clin. Immunol, 125, pp.76~87 (2007)
58. John, L. B., "Oncolytic virus and anti-4-1BB combination therapy elicits strong anti-tumor immunity against established cancer", Cancer Res, 72, pp.1651~1660 (2012)
59. Choi, B. K., "Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy", Cancer Res, 67, pp.8891~8899 (2007)
60. Geiger, J. D., "Generation of T-cell reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases", J. Immunother. Emphasis Tumor Immunol, 13, pp.153~165 (1993)
61. Kim, Y. H., "Mechanisms involved in synergistic anti-cancer effects of anti-4-1BB and cyclophosphamide therapy", Mol. Cancer Ther, 8, pp.469~478 (2009)
62. Ju, S. A., "Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumor-infiltrating lymphocytes", Immunol. Cell Biol, 83, pp.344~351 (2005)
63. Lindsedt, M., "Expression of CD137 (4-1BB) on human follicular dendritic cells", Scand. J. Immunol, 57, pp.305~310 (2003)
64. Sun, Y., "Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling", J. Immunol, 175, pp.884~890 (2005)
65. Middendorp, S., "Mice deficient in CD137 ligand are predisposed to develop germinal center- derived B-cell lymphoma", Blood, 114, pp.2280~2289 (2009)
66. Vinay, D. S., "CD137-deficient mice have reduced NK", NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses, 2004, pp.173, 4218~4229
67. Choi, B. K., "Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-γ", J. Immunol, 185, pp.1404~1411 (2010)
68. Zhang, N., "Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors", Clin. Cancer Res, 13, pp.2758~2767 (2007)
69. Meseck, M., "A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer", J. Immunother, 34, pp.175~182 (2011)
70. Porter, D. L., "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", New. England. J. Med, 365, pp.725~733 (2011)

관련 논문AI추천